Susquehanna International Group
ELVN icon

Susquehanna International Group’s Enliven Therapeutics ELVN Stock Holding History

Susquehanna International Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.67M Buy
+68,100
New +$1.89M ﹤0.01% 5521
2024
Q3 		– Sell
-8,700
Closed -$203K – 12213
2024
Q2 		$203K Buy
+8,700
New +$183K ﹤0.01% 10327
2023
Q4 		– Sell
-10,900
Closed -$149K – 12563
2023
Q3 		$149K Buy
+10,900
New +$184K ﹤0.01% 10549
2023
Q2 		– Sell
-179,500
Closed -$3.93M – 12314
2023
Q1 		$3.93M Buy
179,500
+136,100
+314% +$2.77M ﹤0.01% 3821
2022
Q4 		$710K Sell
43,400
-15,525
-26% -$248K ﹤0.01% 6986
2022
Q3 		$537K Buy
+58,925
New +$348K ﹤0.01% 8288

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group's ELVN Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Enliven Therapeutics (ELVN) in Q1 2026: 25,172 shares worth $987K. The stake represents ﹤0.01% of the portfolio and ranks #7919 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in ELVN as recently as Q3 2025.

Susquehanna International Group first reported a position in ELVN in Q3 2021 and has held it in 10 quarters since. The position peaked at $1.12M in Q2 2025. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Susquehanna International Group held 25,172 shares of Enliven Therapeutics worth $987K as of Q1 2026.
  • Enliven Therapeutics was a new Susquehanna International Group position in Q1 2026.
  • Enliven Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7919 holding.
  • Susquehanna International Group first reported a position in Enliven Therapeutics in Q3 2021 and has held it in 10 quarters since.
  • Susquehanna International Group's Enliven Therapeutics position peaked at $1.12M in Q2 2025.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.